PharmaShots Weekly Snapshot (September 02 – 06, 2019)

1.Roche’s Tecentriq + Chemotherapy Receives EC’s Approval as 1L Treatment for Extensive Stage Small Cell Lung Cancer

Published: Sept 06, 2019 | Tags: Roche, Tecentriq, Chemotherapy, Receives, EC, Approval, Initial Treatment, Extensive Stage Small Cell Lung Cancer

2. OncoCyte to Acquire Razor Genomics for the Expansion of its Capabilities in Early-Stage Lung Cancer

Published: Sept 05, 2019 | Tags: Novartis, Signs, Option Agreement, Iconic Therapeutics, Ophthalmology Program

3. BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate-548 Study for Patients Newly Diagnosed with MGMT-Methylated Glioblastoma Multiforme

Published: Sept 05, 2019 | Tags: BMS, Nivolumab, MGMT-Methylated Glioblastoma Multiforme, NewlyDiagnosed, Opdivo, P-III, Checkmate-548, Study, Patients, Reports, Results

4. SpeeDx’s ResistancePlus MG FleXible Receives CE-IVD Clearance for Detection of Sexually Transmitted Infection (STI)

Published: Sept 06, 2019 | Tags: Cantargia, Extends, Licensing Agreement, BioWa, POTELLIGENT Technology

5.AstraZeneca Signs a License Agreement with Theragnostics for its PARP Inhibitor

Published: Sept 06, 2019 | Tags: AstraZeneca, Signs, License Agreement, Theragnostics, PARP Inhibitor

6.Takeda Recalls Natpara (parathyroid hormone) Injection Formulation in the US

Published: Sept 06, 2019 | Tags: Takeda, Recalls, Natpara, parathyroid hormone, Injection, US

7.Roche’s Tecentriq Based Combination Therapy Receives EC’s Approval as 1L Treatment for Non-Squamous Non-Small Cell Lung Cancer

Published:  Sept 06, 2019 | Tags:  Roche, Tecentriq, EC, Approval, 1L, Treatment, Non-Squamous Non-Small Cell Lung Cancer

8.Novartis Signs an Exclusive Research and Option to Acquire Agreement with IFM Due to Develop Therapies Targeting cGAS/STING Pathway

Published: Sept 05, 2019 | Tags: Novartis, Enters, Exclusive, Option Agreement, IFM Therapeutics, Develop, Therapies, Targeting, cGAS/STING Pathway

9.AbbVie Signs a Research Agreement with Idera Pharmaceuticals to Evaluate Combination Therapy

Published: Sept 04, 2019 | Tags: AbbVie, Signs, Research Agreement, Idera Pharmaceuticals, Evaluate; Combination Therapy

10.Janssen’s Stelara (ustekinumab) Receives EC’s Approval for its Expanded Use to Treat Moderately to Severely Active Ulcerative Colitis

Published: Sept 04, 2019 | Tags: Janssen, Stelara, ustekinumab, Receives, European Commission, Approval, Expanded Use, Moderately to Severely Active Ulcerative Colitis

11. BioNTech Signs an Agreement with Gates Foundation to Develop Therapies for HIV and Tuberculosis

Published: Sept 04, 2019 | Tags: BioNTech, Signs, Agreement, Gates Foundation, Develop, HIV, Tuberculosis

12.Google Collaborates with Cochlear and GN Hearing to Support Direct Phone Streaming to Hearing Aids for Patients with Hearing Loss

Published: Sept 05, 2019 | Tags: Google, Collaborates, Cochlear, GN Hearing, Support, Direct Phone Streaming, Hearing Aids

13.AstraZeneca Collaborates with Schrödinger to Utilize its Molecule-Modeling Platform for Drug Discovery

Published: Sept 04, 2019 | Tags: AstraZeneca, Collaborates, Schrödinger, Molecule-Modeling Platform, Drug Discovery

14.BMS Signs an Agreement with BioMotiv to Develop Therapies for Patients with Serious Disorder

Published: Sept 04, 2019 | Tags: BMS, BioMotiv, Agreement, Serious Disorders, Develop, Therapies

15.Regenxbio Signs an Exclusive Worldwide Option and License Agreement with Clearside Biomedical to Evaluate its Delivery Platform for RGX-314

Published: Sept 04, 2019 | Tags: Regenxbio, Signs, Exclusive, Worldwide, Option and License Agreement, Clearside Biomedical, Evaluate, Delivery Platform, RGX-314

16.Janssen’s Investigational Prophylactic Vaccine Receives the US FDA’s Breakthrough Therapy Designation to Prevent Respiratory Syncytial Virus

Published: Sept 03, 2019 | Tags: Janssen, Investigational, Prophylactic Vaccine, Receives, US FDA, Breakthrough Therapy Designation, Respiratory Syncytial Virus

17.Karolinska Institutet Evaluates AsthmaTuner Self-monitoring Mobile App for Managing Uncontrolled Asthma

Published: Sept 03, 2019 | Tags: Vivus, Reports, Results, Qsymia, Pilot Clinical Study, Patients, Laparoscopic Sleeve Gastrectomy Surgery

18. Merck’s Keytruda (pembrolizumab) in Combination with Inlyta (axitinib) Receives European Commission’s Approval as a 1L Therapy for Advanced Renal Cell Carcinoma

Published: Sept 04, 2019 | Tags: Merck, Keytruda, pembrolizumab, Inlyta, axitinib, European Commission, Approval, 1L, Therapy, Advanced Renal Cell Carcinoma

19.Karolinska Institutet Evaluates AsthmaTuner Self-monitoring Mobile App for Managing Uncontrolled Asthma

Published: Sept 03, 2019 | Tags: Karolinska Institutet, Evaluates, AsthmaTuner, Self-monitoring, Mobile App, Uncontrolled Asthma

20.Boehringer Ingelheim Enters into a Licensing Agreement with Lupin to Expand its KRAS Cancer Program

Published: Sept 04, 2019 | Tags: Boehringer Ingelheim, Enters, Licensing Agreement, Lupin, Expand, KRAS Cancer Program

21.AstraZeneca’s Tagrisso (osimertinib) Receives NMPA’s Approval as a 1L Therapy for EGFR-Mutated Non-Small Cell Lung Cancer in China

Published: Sept 04, 2019 | Tags: AstraZenca, Tagrisso, osimertinib, Receives, NMPA, Approval, 1L, Therapy, EGFR Mutated Non-Small Cell Lung Cancer, China

22. Celltrion Enters into a Contract to Manufacture Agreement for its Remsima (biosimilar, infliximab) with Lonza

Published: Sept 03, 2019 | Tags: Celltrion, Enters, Contract to Manufacture, Agreement, Lonza, Biosimilar, Remsima

23.Vertex to Acquire Semma Therapeutics for Developing Curative Cell-Based Therapies to Treat Type 1 Diabetes

Published: Sept 03, 2019 | Tags: Vertex, Acquire, Semma Therapeutics, Developing, Curative Cell-Based Therapies, Type 1 Diabetes

24.Alytas Therapeutics Signs an Agreement with Velabs Therapeutics to Develop Novel Immune-Based Therapy for Obesity

Published: Sept 03, 2019 | Tags: Alytas Therapeutics, Signs, Agreement, Velabs Therapeutics, Develop, Novel, Immune-Based Therapy, Obesity

25. The European Society of Cardiology Recommends Bayer’s Xarelto (rivaroxaban) in Combination with Aspirin for the Management of Diabetes and Chronic Coronary Syndromes

Published: Sept 02, 2019 | Tags: The European Society of Cardiology, Recommends, Bayer, Xarelto, rivaroxaban, Aspirin, Diabetes, Chronic Coronary Syndromes

26.Polpharma Signs an Exclusive Worldwide Commercialization Agreement with Sandoz for Proposed Biosimilar Natalizumab to Treat Relapsing-Remitting Multiple Sclerosis

Published: Sept 03, 2019 | Tags: Polpharma, Signs, Exclusive, Worldwide, Commercialization, Agreement, Sandoz, Proposed Biosimilar, Natalizumab, Relapsing-Remitting Multiple Sclerosis

27.Helsinn Enters into an Exclusive Distribution and License Agreement with Blanver and Varifarma for Pracinostat in South America

Published: Sept 02, 2019 | Tags: Helsinn, Enters, Exclusive, Distribution, License, Agreement, Blanver, Varifarma, Pracinostat, South America

28. Boehringer Ingelheim and Zealand Pharma to Initiate P-II Study of BI 456906 for Obesity and Diabetes

Published: Sept 03, 2019 | Tags: Boehringer Ingelheim, Zealand Pharma, Initiate, P-II Study, BI 456906, Obesity, Diabetes

29.AstraZeneca Reports Detailed Results of Farxiga (dapagliflozin) in P-III DAPA-HF Study to Treat Patients with Heart Failure

Published: Sept 01, 2019 | Tags: AbbVie, Rinvoq, upadacitinib, Receives, US, FDA, Approval, Moderate, Severe, Rheumatoid Arthritis

30.Chugai Files an Application to MHLW for an Additional Indication of Kadcyla (trastuzumab emtansine) as an Adjuvant Therapy for HER2-Positive Early Breast Cancer in Japan

Published: Aug 30, 2019 | Tags: AbbVie, Rinvoq, upadacitinib, Receives, US, FDA, Approval, Moderate, Severe, Rheumatoid Arthritis

31.AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Study for Coronary Artery Disease and Type-2 Diabetes

Published: Sept 01, 2019 | Tags: AbbVie, Rinvoq, upadacitinib, Receives, US, FDA, Approval, Moderate, Severe, Rheumatoid Arthritis

32.UniSA Evaluates Computer Vision Technology to Monitor Premature Babies in Neonatal Units

Published: Aug 30, 2019 | Tags: AbbVie, Rinvoq, upadacitinib, Receives, US, FDA, Approval, Moderate, Severe, Rheumatoid Arthritis

33.Novartis Reports Results of Entresto (sacubitril/valsartan) in Three P-III PARAGON-HF and P-IV PROVE-HF with EVALUATE-HF Studies for Patients with HFpEF and HFrEF

Published: Aug 06, 2019 | Tags: AbbVie, Rinvoq, upadacitinib, Receives, US, FDA, Approval, Moderate, Severe, Rheumatoid Arthritis

34.Roche Reports Positive Results of Xofluza (baloxavir marboxil) in Two P-III MINISTONE-2 and BLOCKSTONE Studies for Influenza Infection

Published: Sept 02, 2019 | Tags: AbbVie, Rinvoq, upadacitinib, Receives, US, FDA, Approval, Moderate, Severe, Rheumatoid Arthritis

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post